Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

86.28 -0.30 (-0.35%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer. 
Via Investor's Business Daily
1 Profitable Stock to Own for Decades and 2 We Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
Topics Economy
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed statistical significance thresholds. 
Via Benzinga
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Merck’s Investigational Drug Shows Reduction In Cholesterol In Late-stage Trial
Via Stocktwits
Robert F. Kennedy Took Fire From Both Republicans And Democrats Over Vaccine Overhauls: GOP Senators Defend Trump's Operation Warp Speed
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial... 
Via Benzinga
Topics Government
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
3 Things You Need to Know if You Buy Pfizer Today
Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space? 
Via The Motley Fool
Topics Intellectual Property
Robert F. Kennedy Jr.'s Vaccine Shake-Up Sparks Coast-To-Coast Divide: West Coast Creates Health Alliance, Florida Rolls Back Requirements
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates. 
Via Benzinga
Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster'
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public... 
Via Benzinga
Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades
Rep. Marjorie Taylor Greene buys Google stock just days before a key antitrust ruling. See her latest trades and portfolio performance. 
Via Benzinga
This Merck Pill Promises Powerful Cholesterol Reduction Without Injections
Merck's Coralreef Lipids trial showed enlicitide cut LDL-C and other lipid markers, while pooled Verquvo data hinted at heart failure benefits. 
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors. 
Via The Motley Fool
Topics Stocks
Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 We Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens
Senator Bernie Sanders called for HHS Secretary RFK Jr.'s resignation over his anti-vaccine policies, ousting of CDC Director Susan Monarez. 
Via Benzinga
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock
Discover Merck (MRK), a top dividend stock with a 3.76% yield, strong growth history, and excellent financial health for sustainable income. 
Via Chartmill
Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction
From Merck & Co., Inc.
Via Business Wire
Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public... 
Via Benzinga
Topics Government
Merck to Participate in the 2025 Wells Fargo Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
1 Safe-and-Steady Stock Worth Your Attention and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
Topics Bonds
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst
Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger. 
Via Benzinga
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
EU Rushes To Scrap Tariffs On US Goods To Unlock Lower American Auto Duties: These Exporters Stand To Gain Big
EU set to scrap tariffs on U.S. goods in a key auto trade deal. See which American industrial and energy stocks are poised for a boost. 
Via Benzinga
Topics World Trade
HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy
From Merck & Co., Inc.
Via Business Wire
Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside
Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy. 
Via Stocktwits
As the Market Rotates, This Healthcare ETF Is Leading the Way
Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure. 
Via MarketBeat
Topics ETFs
Explore the top gainers and losers within the S&P500 index in today's session.
Stay updated with the movements of the S&P500 index in the middle of the day on Monday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
Top 5 ETFs and Stocks to Watch as the Fed Eyes Rate Cuts
Powell’s dovish Jackson Hole remarks signal that the Fed could cut rates as early as September, with markets now pricing an 80% chance of a 25 bps cut. 
Via MarketBeat
Topics ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.